AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8546739 — intervention group
Group type: COMPARATOR
Intervention: Polymer-based saliva substitutes (3 types)
Number of subjects: 43
Study 8546739 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylic acid-based saliva substitutes
Number of subjects: 43
Study 8546739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscoelastic saliva substitutes
Number of subjects: 43
Study 1712270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 164
Study 1712270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 164
Study 1712270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 6406459 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (100, 200, and 400 mg)
Number of subjects: 13
Study 6406459 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine sulfate (15 and 30 mg)
Number of subjects: 13
Study 6406459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3873175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone antenatal therapy
Number of subjects: 2
Study 3873175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31710096 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based interventions (prohibition of sugary snack consumption, teacher supervised daily brushing using fluoridated toothpaste, oral health education)
Number of subjects: 420
Study 31710096 — intervention group
Group type: COMPARATOR
Intervention: Active control (tooth brushing and oral health education)
Number of subjects: 420
Study 31710096 — intervention group
Group type: COMPARATOR
Intervention: Negative control (only oral health education)
Number of subjects: 420
Study 30053283 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 39% (P < 0.05) compared to baseline.
Number of subjects: 101
Study 30053283 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic acid-canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 34% (P < 0.05) compared to baseline.
Number of subjects: 101
Study 30053283 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched high oleic acid-canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 55% (P < 0.05) compared to baseline.
Number of subjects: 101
Study 30053283 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil and safflower oil blend diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 49% (P < 0.05) compared to baseline.
Number of subjects: 101
Study 30053283 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax oil and safflower oil blend diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 51% (P < 0.05) compared to baseline.
Number of subjects: 101
Study 27271136 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week meditation program
Number of subjects: 50
Study 27271136 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 24942012 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymeric scaffolds
Number of subjects: 303
Study 22410646 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 1940
Study 22410646 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 1940
Study 20511294 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI < 0.50
Number of subjects: 156
Study 20511294 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI 0.50-0.70
Number of subjects: 156
Study 20511294 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI 0.71-0.95
Number of subjects: 156
Study 18641036 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of Triomune 40 (stavudine 40 mg, lamivudine 150 mg, nevirapine 200 mg)
Number of subjects: 16
Study 18641036 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation of Triomune 40 (stavudine 40 mg, lamivudine 150 mg, nevirapine 200 mg)
Number of subjects: 16
Study 18641036 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of Triomune 40
Number of subjects: 16
Study 18641036 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation of Triomune 40
Number of subjects: 16
Study 18641036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 16
Study 15607260 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (T)
Number of subjects: 28
Study 15607260 — intervention group
Group type: COMPARATOR
Intervention: Reference product (R)
Number of subjects: 28
Study 14569644 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 1/2 hour educational program for staff
Number of subjects: 40
Study 14569644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 40
Study 10536549 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine plus diclofenac 1 mg kg‐1
Number of subjects: 80
Study 10536549 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine plus paracetamol 15-20 mg kg‐1
Number of subjects: 80
Study 10536549 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine plus a combination of both diclofenac and paracetamol
Number of subjects: 80
Study 10536549 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine alone
Number of subjects: 80
Study 8923399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination (active intensity of 2.0 W/cm2)
Number of subjects: 78
Study 8923399 — intervention group
Group type: COMPARATOR
Intervention: Bone scintiscan (reference standard)
Number of subjects: 78
Study 1681264 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet after fasting
Number of subjects: 53
Study 1681264 — intervention group
Group type: COMPARATOR
Intervention: Control group (ordinary diet)
Number of subjects: 53
Study 31482947 — intervention group
Group type: EXPERIMENTAL
Intervention: Saltier bread samples (no specific dosage mentioned)
Number of subjects: 118
Study 31482947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with oregano seasoning (no specific dosage mentioned)
Number of subjects: 118
Study 31482947 — intervention group
Group type: COMPARATOR
Intervention: Lowest salt concentration sample
Number of subjects: 118
Study 30063372 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter season
Number of subjects: 1175
Study 30063372 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring season
Number of subjects: 1175
Study 30063372 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer season
Number of subjects: 1175
Study 30063372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall season
Number of subjects: 1175
Study 30063372 — intervention group
Group type: EXPERIMENTAL
Intervention: Southeast and West regions
Number of subjects: 1175
Study 27592725 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow bed (emergency stretcher)
Number of subjects: 0
Study 27592725 — intervention group
Group type: COMPARATOR
Intervention: Wide bed (standard hospital bed)
Number of subjects: 0
Study 25744418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-consumption group (400 g/d for 24 wk)
Number of subjects: 200
Study 25744418 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary intervention focused on weight control)
Number of subjects: 200
Study 22247420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk genetic results
Number of subjects: 175
Study 22247420 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk genetic results
Number of subjects: 175
Study 19188391 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem (500 mg every 8 hours)
Number of subjects: 24
Study 19188391 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (250 mg every 24 hours)
Number of subjects: 24
Study 18221624 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment step 1
Number of subjects: 0
Study 18221624 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment step 2
Number of subjects: 0
Study 18221624 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment step 3
Number of subjects: 0
Study 18221624 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment step 4
Number of subjects: 0
Study 18221624 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing treatment steps
Number of subjects: 0
Study 18221624 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up in remission
Number of subjects: 0
Study 15888130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline oil pretreatment with UVB TL01 phototherapy
Number of subjects: 15
Study 15888130 — intervention group
Group type: COMPARATOR
Intervention: Control (no vaseline oil pretreatment)
Number of subjects: 15
Study 12060043 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg once daily
Number of subjects: 256
Study 12060043 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg twice daily
Number of subjects: 256
Study 12060043 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole
Number of subjects: 256
Study 10474492 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted analysis of lung area on chest radiograph
Number of subjects: 50
Study 10474492 — intervention group
Group type: COMPARATOR
Intervention: Functional residual capacity (FRC) measurement
Number of subjects: 50
Study 9139274 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6 urinary excretion in IDDM patients with albuminuria (mean = 7.43 +/‐ 8.29 pg/mg creatinine)
Number of subjects: 12
Study 9139274 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐beta urinary excretion in IDDM patients with albuminuria (mean = 42.0 +/‐ 30.0 pg/mg creatinine)
Number of subjects: 12
Study 1860294 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 14
Study 1860294 — intervention group
Group type: COMPARATOR
Intervention: 0.1% chlorhexidine mouthrinse
Number of subjects: 14
Study 6662638 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 124
Study 6662638 — intervention group
Group type: COMPARATOR
Intervention: Heparin-DHE
Number of subjects: 124
Study 6662638 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection in the upper arm
Number of subjects: 124
Study 6662638 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous thrombin administration
Number of subjects: 124
Study 29975331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) preconditioning
Number of subjects: 48
Study 29975331 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord ischemia-reperfusion (I/R)
Number of subjects: 48
Study 29975331 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 48
Study 30289907 — intervention group
Group type: COMPARATOR
Intervention: Unloaded condition
Number of subjects: 18
Study 30289907 — intervention group
Group type: EXPERIMENTAL
Intervention: Load corresponding to 20% of body mass (BM)
Number of subjects: 18
Study 30289907 — intervention group
Group type: EXPERIMENTAL
Intervention: Load corresponding to 30% of body mass (BM)
Number of subjects: 18
Study 30289907 — intervention group
Group type: EXPERIMENTAL
Intervention: Load corresponding to 40% of body mass (BM)
Number of subjects: 18
Study 26376953 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar strap
Number of subjects: 97
Study 26376953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports tape
Number of subjects: 97
Study 26376953 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 97
Study 26376953 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study 24695897 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 33
Study 24695897 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 33
Study 24695897 — intervention group
Group type: COMPARATOR
Intervention: No nutrition (control)
Number of subjects: 33
Study 22495696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet and exercise intervention (Mediterranean and macrobiotic diet, moderate physical activity)
Number of subjects: 1208
Study 22495696 — intervention group
Group type: COMPARATOR
Intervention: General lifestyle recommendations for cancer prevention
Number of subjects: 1208
Study 19755402 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban vs. Placebo
Number of subjects: 20006
Study 19755402 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban vs. Abciximab
Number of subjects: 20006
Study 18663487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group training protocol (exercise therapy, back school, operant-conditioning principles)
Number of subjects: 114
Study 18663487 — intervention group
Group type: COMPARATOR
Intervention: Guideline physiotherapy (usual care according to Dutch guidelines for Low Back Pain)
Number of subjects: 114
Study 16204716 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV(100) normalized by serum glucose with a g-value of -0.5
Number of subjects: 102
Study 16204716 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV(100) normalized by serum glucose with a g-value of -0.5 in patients with extreme glucose values
Number of subjects: 102
Study 16204716 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold SUV(100) of 7.25
Number of subjects: 102
Study 11846115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively-based National Cancer Institute (NCI) Diet History Questionnaire
Number of subjects: 623
Study 11846115 — intervention group
Group type: COMPARATOR
Intervention: 1992 NCI-Block Health Habits and History Questionnaire
Number of subjects: 623
Study 11846115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches (cognitively-based NCI FFQ and 1992 NCI-Block FFQ)
Number of subjects: 623
Study 10206443 — intervention group
Group type: EXPERIMENTAL
Intervention: TVP‐low‐cholesterol diet (17 to 30 mg/d)
Number of subjects: 8
Study 10206443 — intervention group
Group type: EXPERIMENTAL
Intervention: TVP (soybean protein)
Number of subjects: 8
Study 10206443 — intervention group
Group type: COMPARATOR
Intervention: Standard cholesterol diet (190 to 550 mg/d)
Number of subjects: 8
Study 10206443 — intervention group
Group type: EXPERIMENTAL
Intervention: TVP‐standard cholesterol diet
Number of subjects: 8
Study 7639017 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine strain, administered as 4 doses of ca. 7 x 10(8) c.f.u. on days 0, 3, 14, and 17
Number of subjects: 21
Study 7639017 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 21
Study 7639017 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine strain
Number of subjects: 21
Study 2771322 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovision correction; near additions of +1.50 D, +2.50 D, and no addition
Number of subjects: 18
Study 2771322 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance contact lenses with lookover spectacles, soft progressive bifocal contact lenses, soft concentric bifocal contact lenses, monovision contact lenses, modified monovision contact lenses, hard bifocal contact lenses
Number of subjects: 18
Study 327422 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 24
Study 327422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 24
Study 327422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31343675 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D endoscopy
Number of subjects: 16
Study 31343675 — intervention group
Group type: COMPARATOR
Intervention: 2D endoscopy
Number of subjects: 16
Study 28516381 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during SWL
Number of subjects: 200
Study 28516381 — intervention group
Group type: COMPARATOR
Intervention: No music during SWL (Control)
Number of subjects: 200
Study 25223836 — intervention group
Group type: EXPERIMENTAL
Intervention: Selisistat 5-600 mg single dose
Number of subjects: 56
Study 25223836 — intervention group
Group type: EXPERIMENTAL
Intervention: Selisistat 100-300 mg once daily for 7 days
Number of subjects: 56
Study 25223836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24358480 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling (RMUS)
Number of subjects: 597
Study 24358480 — intervention group
Group type: COMPARATOR
Intervention: Transobturator midurethral sling
Number of subjects: 597
Study 24358480 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized voiding trial at discharge
Number of subjects: 597
Study 24358480 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling urethral catheter management
Number of subjects: 597
Study 24358480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent catheterization
Number of subjects: 597
Study 24358480 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter use at 2 weeks post-surgery
Number of subjects: 597
Study 24358480 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter use at 6 weeks post-surgery
Number of subjects: 597
Study 24358480 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative voiding accommodations
Number of subjects: 597
Study 21469386 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 83
Study 21469386 — intervention group
Group type: COMPARATOR
Intervention: Control (general therapy without HBO)
Number of subjects: 83
Study 19319920 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of patient-reported outcome measures (PROMs) in cancer clinics
Number of subjects: 0
Study 19319920 — intervention group
Group type: EXPERIMENTAL
Intervention: Future interventions to motivate and equip health professionals to use PROM data
Number of subjects: 0
Study 19319920 — intervention group
Group type: EXPERIMENTAL
Intervention: Future trials using cluster-randomized design
Number of subjects: 0
Study 16483397 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acids (LC-PUFA) supplementation
Number of subjects: 42
Study 16483397 — intervention group
Group type: COMPARATOR
Intervention: Phenylalanine-free infant formula without LC-PUFA
Number of subjects: 42
Study 15580812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate with ascorbic acid (4:1 molar ratio)
Number of subjects: 10
Study 15580812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate without ascorbic acid
Number of subjects: 10
Study 15580812 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4 with ascorbic acid (4:1 molar ratio)
Number of subjects: 10
Study 15580812 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4 without ascorbic acid
Number of subjects: 10
Study 15580812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate (mean particle size 6.7 microm)
Number of subjects: 10
Study 15580812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate (mean particle size 12.5 microm)
Number of subjects: 10
Study 11223448 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 or 40 mg daily)
Number of subjects: 20
Study 11223448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9364692 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-12 micrograms intradermal (i.d.) inoculation in three or four divided doses (Groups A-F)
Number of subjects: 173
Study 9364692 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 micrograms intradermal (i.d.) inoculation in four doses
Number of subjects: 173
Study 9364692 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group G) received three 10 micrograms intramuscular (i.m.) inoculations
Number of subjects: 173
Study 7908838 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of sustained-release somatuline
Number of subjects: 15
Study 7908838 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of sustained-release somatuline at 2-week intervals over a 6-month period
Number of subjects: 15
Study 3126708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin combined with mitomycin C and tegafur as an adjuvant to surgery
Number of subjects: 0
Study 31182077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle Maneuver (PM) combined with stapler resection technique
Number of subjects: 106
Study 31182077 — intervention group
Group type: COMPARATOR
Intervention: Stapler resection without the use of Pringle Maneuver (Control)
Number of subjects: 106
Study 28709629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose gel
Number of subjects: 227
Study 28709629 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula
Number of subjects: 227
Study 28709629 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 227
Study 28709629 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk
Number of subjects: 227
Study 28709629 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 227
Study 26846591 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared panel management program (phone call requesting appointment)
Number of subjects: 1676
Study 26846591 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1676
Study 23238301 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented feedback (AF) during tuck-jump assessment
Number of subjects: 37
Study 23238301 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL) feedback during treadmill running
Number of subjects: 37
Study 20721698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (high-dose and low-dose protocols)
Number of subjects: 90
Study 20721698 — intervention group
Group type: COMPARATOR
Intervention: Heparin (standardized protocol)
Number of subjects: 90
Study 19815903 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person visits and telephone intervention (Telephone)
Number of subjects: 303
Study 19815903 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person visits and telemonitoring (Telemonitoring)
Number of subjects: 303
Study 19815903 — intervention group
Group type: COMPARATOR
Intervention: In-person visits alone (Control)
Number of subjects: 303
Study 15011419 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg hyperbaric bupivacaine
Number of subjects: 36
Study 15011419 — intervention group
Group type: COMPARATOR
Intervention: 10 mg hyperbaric bupivacaine
Number of subjects: 36